As of September 30, the company had cash and cash equivalents of approximately $27.7M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio to Host Q3 Results Conference Call
- INmune Bio CEO to Speak at Maxim Growth Summit
- Inmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges
- Inmune Bio Submits Manuscript on Alzheimer’s Trial
- INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia